Elevance Health, Inc. $ELV Stock Holdings Reduced by Hosking Partners LLP

Key Points

• Hosking Partners reduced its Elevance Health stake by 6.4% in the third quarter, selling 9,584 shares and retaining 140,427 shares valued at approximately $54.6 million. Institutional investors collectively own 89.24% of the company.
• Elevance reported strong third-quarter results, with adjusted EPS of $6.99 and revenue of $50.44 billion, both exceeding analyst expectations. Management raised its 2026 earnings outlook to at least $26.75 per share, supported by improved medical-cost management and Carelon growth.
• The stock traded near its 52-week high at $435.26, while analysts maintained an overall “Moderate Buy” rating with an average price target of $441.71. Declining medical membership and potential medical-cost inflation remain key risks despite the stronger outlook.

Hosking Partners LLP lowered its holdings in Elevance Health, Inc. (NYSE:ELV - Free Report) by 6.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 140,427 shares of the company's stock after selling 9,584 shares during the quarter. Elevance Health accounts for 1.9% of Hosking Partners LLP's holdings, making the stock its 15th largest holding. Hosking Partners LLP owned 0.06% of Elevance Health worth $54,601,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Elevance Health during the second quarter worth $7,344,424,000. State Street Corp grew its holdings in shares of Elevance Health by 1.3% in the second quarter. State Street Corp now owns 10,426,610 shares of the company's stock valued at $4,032,283,000 after purchasing an additional 137,914 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Elevance Health by 12.0% during the 2nd quarter. Wellington Management Group LLP now owns 9,213,513 shares of the company's stock worth $3,563,142,000 after buying an additional 984,976 shares in the last quarter. First Eagle Investment Management LLC boosted its position in Elevance Health by 1.4% in the 2nd quarter. First Eagle Investment Management LLC now owns 4,188,196 shares of the company's stock valued at $1,619,701,000 after buying an additional 55,905 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in Elevance Health in the 2nd quarter valued at approximately $1,246,349,000. Institutional investors and hedge funds own 89.24% of the company's stock.

Key Stories Impacting Elevance Health

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Quarterly results exceeded expectations: Adjusted earnings were $6.99 per share versus the roughly $4.66–$4.71 consensus estimate, while revenue reached $50.44 billion, above expectations of about $49.22 billion. Earnings also increased from $6.03 per share a year earlier. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: 2026 outlook was raised: Management lifted its underlying earnings baseline to at least $26.75 per share, citing disciplined expense management and better medical-cost performance. Elevance also expects at least 12% adjusted EPS growth in 2027 from the higher earnings base. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon remained a growth driver: Strength in the services business helped offset pressure elsewhere, supporting management’s confidence in future growth. Elevance named Jeff Park president of Carelon, effective December 1, to lead its next expansion phase. Elevance Health Names Jeff Park President of Carelon
• Neutral Sentiment: Elevance declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%. The payout supports shareholder returns but is unlikely to be the primary near-term trading catalyst.
• Negative Sentiment: Membership pressure remains a concern: The earnings beat occurred despite declining medical membership, increasing investor focus on enrollment trends and the company’s ability to sustain growth.
• Negative Sentiment: Although cost management improved, Elevance operates on a thin net margin, and continued medical-cost inflation or weaker enrollment could limit the benefit of the raised forecast. The shares have also recently traded near a 52-week high, potentially increasing profit-taking risk.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Truist Financial boosted their price target on shares of Elevance Health from $450.00 to $475.00 and gave the stock a "buy" rating in a research note on Tuesday, July 14th. Weiss Ratings reiterated a "hold (c)" rating on shares of Elevance Health in a research note on Thursday, August 13th. TD Cowen lifted their target price on Elevance Health from $400.00 to $465.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Cantor Fitzgerald lifted their target price on Elevance Health from $400.00 to $450.00 and gave the company an "overweight" rating in a report on Tuesday, July 7th. Finally, Royal Bank Of Canada lowered their target price on Elevance Health from $439.00 to $424.00 and set a "sector perform" rating for the company in a research note on Thursday, July 16th. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $441.71.

Elevance Health Trading Down 1.1%

NYSE ELV opened at $435.26 on Thursday. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a 52 week low of $274.84 and a 52 week high of $450.69. The stock has a market capitalization of $94.39 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 2.29 and a beta of 0.70. The firm has a 50 day moving average of $406.59 and a two-hundred day moving average of $389.52.

Elevance Health (NYSE:ELV - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share for the quarter, beating analysts' consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The business had revenue of $50.44 billion for the quarter, compared to analyst estimates of $49.28 billion. The company's revenue was up .7% on a year-over-year basis. During the same period last year, the business earned $6.03 EPS. As a group, research analysts expect that Elevance Health, Inc. will post 27.20 EPS for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health's dividend payout ratio (DPR) is currently 30.58%.

Elevance Health Profile

Elevance Health, Inc NYSE: ELV is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.